UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



FORM 20-F/A

(Amendment No. 1)



(Mark One)



| ̈  | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
|-- | ----------------------------------------------------------------------------------------------
|OR
|   |                                                                                               
|x  | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934          
|   | For the fiscal year ended  December 31, 2013                                                  
|   |                                                                                               
|OR
|   |                                                                                               
| ̈  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934      
|   |                                                                                               
|OR
|   |                                                                                               
| ̈  | SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   



| | Date of event requiring this shell company report________________________
| | -------------------------------------------------------------------------
| |                                                                          
| | For the transition period from__________ to ___________                  
| |                                                                          

Commission file number
001-36288



|Celsus Therapeutics PLC                               
|------------------------------------------------------
|(Exact name of Registrant as specified in its charter)



|The Laws of England and Wales                  
|-----------------------------------------------
|(Jurisdiction of incorporation or organization)



|53 Davies Street, London, United Kingdom W1K 5JH
|------------------------------------------------
|(Address of principal executive offices)        





|Mr. Mark S. Cohen
        Executive Chairman
        53
        Davies StreetLondon W1K 5JHUnited KingdomTelephone +44 20 3322 1321
|-----------------------------------------------------------------------------------------------------------------------------------
|(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)                                            







|Securities registered or to be registered pursuant to Section 12(b) of the Act.                                                                          |  |                                          
|-------------------------------------------------------------------------------------------------------------------------------------------------------- |  | -----------------------------------------
|                                                                                                                                                         |  |                                          
|Title of each class                                                                                                                                      |  | Name of each exchange on which registered
|                                                                                                                                                         |  |                                          
|American Depositary Shares,
each representing 10 Ordinary Shares, par value £0.01 per share
        
        Ordinary Shares, £0.01
par value per share* |  | The Nasdaq Capital Market                





Securities registered or to be registered
pursuant to Section 12(g) of the Act.None



Securities for which there is a reporting
obligation pursuant to Section 15(d) of the Act. None











The number of outstanding
shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:
40,227,953 Ordinary Shares, £0.01 par value per share**



| | * | Not for trading, but only in connection with the registration
of American Depositary Shares representing such Ordinary Shares pursuant to the requirements of the Securities and Exchange Commission.
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | ** | In addition, the Company has 633,333 Deferred B Shares,
£0.001 par value per share, and 400,000 Deferred C Shares, £0.001 par value per share.  All of such Deferred
B and Deferred C Shares are outstanding but have expired and are no longer exercisable into Ordinary Shares.
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.



 ̈YesxNo



If this report is an annual or transition
report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.



 ̈YesxNo



Note – Checking the box above will
not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from
their obligations under those Sections.



Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.



xYes ̈No



Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files).



xYes ̈No



Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated
filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):



|Large accelerated filer ̈ | Accelerated filer ̈ | Non-accelerated filerx
|------------------------ | ------------------ | ----------------------



Indicate by check mark
which basis of accounting the registrant has used to prepare the financial statements included in this filing:



|U.S. GAAPx | International Financial Reporting Standards as issued by the International Accounting Standards Board ̈ | Other ̈
|---------- | ------------------------------------------------------------------------------------------------------ | ------



If “Other”
has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has
elected to follow.

 ̈Item 17 ̈Item 18



If this is an annual report, indicate by
check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).



 ̈YesxNo











EXPLANATORY NOTE





This Amendment No. 1 on Form 20-F/A is being
filed by Celsus Therapeutics PLC to amend its Annual Report on Form 20-F for the fiscal year ended December 31, 2013, originally
filed with the Securities and Exchange Commission on March 24, 2014 (“2013 Form 20-F”), to include Exhibit 15.1 (Consent
of independent registered public accounting firm), which was inadvertently omitted from the original filing.



This Form 20-F/A consists of a cover page,
this explanatory note, the signature page and Exhibit 15.1.  Except as provided above, no other changes have been made to
the 2013 Form 20-F. Other than as expressly set forth above, this Form 20-F/A does not, and does not purport to, amend, update
or restate any information received or reflect any events that have occurred after the 2013 Form 20-F was filed.















SIGNATURES



The registrant hereby certifies that it
meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this annual
report on its behalf.



| | Celsus Therapeutics PLC
| | -----------------------
| |                        
| | By:                    
| |                        
| |                        



Date:  April 7, 2014